? Operator Finance Network Internship student Liu Jiawen / Written by
Recently, a subsidiary of Fosun Pharma Holding Company signed a (cooperation framework agreement) with Sandoz, a global leader in biosimilar drugs. In reviewing Fosun Pharma’s core management team, Operator Finance Network noted the relatively new Chief Financial Officer, Huang Zhi, and attempted to sort through his past experience.
Public information shows that Huang Zhi graduated from the business school of Daldin University in the U.S., and holds a master’s degree in banking and finance.
Baidu Baike shows that Daldin University in the U.S. is a private liberal arts and comprehensive college in New York founded in 1955. In 2014, the school’s credit rating was downgraded to Ca by Moody’s due to a decline in enrollment rate and failure to pass fiscal indicators. On June 3, 2016, it officially announced its closure due to accumulated liabilities of $54 million.
Moreover, current publicly available information has not disclosed which undergraduate institution he attended, so it is unclear what his first degree is.
In April 2007, Huang Zhi joined Novartis Pharmaceuticals. Over the following 13 years, he successively held roles such as Business Planning and Analysis Manager for Novartis’ U.S. Oncology Business Unit and Chief Financial Officer of Korea, among others.
In October 2020, he joined BeiGene. He successively served as Chief Financial Officer for Greater China and head of finance at the Innovation Center, among other roles. From June 2023 to February 2025, he further served as BeiGene’s Global Commercial Finance负责人.
In May 2025, Huang Zhi joined Ascentage Pharma and served as Senior Vice President for Global Corporate Development and Finance.
It should be noted that Huang Zhi’s tenure at Ascentage Pharma was not long. According to the publicly available resume, he ended that assignment in January 2026. After that, he joined Fosun Pharma in February 2026—meaning the gap between leaving Ascentage Pharma and entering Fosun Pharma was only one month.
In February 2026, Huang Zhi officially joined Fosun Pharma as Senior Vice President and Co-President of the Innovative Drug Business Unit. On April 2, 2026, he was appointed as Senior Vice President and Chief Financial Officer.
It is worth noting that BeiGene is a leading company in global oncology treatment and a benchmark for China’s innovative drugs going global. Huang Zhi was appointed as the co-president of the Innovative Drug Business Unit, which also fits him very well.
According to Fosun Pharma’s 2026 Q1 performance report, the company achieved operating revenue of RMB 10.073 billion, representing a year-on-year increase of 6.93%; and attributable net profit of RMB 871 million, representing a year-on-year increase of 13.87%. Judging from the company’s current operating performance, both revenue and profit are growing.
As Chief Financial Officer, how Huang Zhi will help drive the development of Fosun Pharma’s innovative drug business—Operator Finance Network will continue to monitor.
(责任编辑：康玲华）